SAN DIEGO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:
Date:	February 28, 2017
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in:	(855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode:	73756754
Via web:	www.traconpharma.com; “Events and Presentation” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:		
                  Casey Logan			
                  Chief Business Officer		
                  (858) 550-0780 ext. 236		
                  clogan@traconpharma.com 
                  	
                  Investor Contact:
                  Andrew McDonald
                  LifeSci Advisors LLC
                  646-597-6987
                  Andrew@lifesciadvisors.com